FiercePharma

Merck advances Winrevair in subset of heart failure patients

Positive results from a proof-of-concept study evaluating Merck’s Winrevair pave the way for further study of the activin signaling inhibitor as a potential treatment for a subset of heart failure ...
Wall Street Journal

Merck to Buy Cidara Therapeutics in $9.2 Billion Deal

Merck MRK1.30%increase; green up pointing triangle & Co. has struck a $9.2 billion deal to buy biotechnology company Cidara Therapeutics CDTX 0.21%increase; green up pointing triangle in a move that ...
STAT

Merck’s pill to reduce cholesterol on top of statins matches results from injectables

Elizabeth Cooney is a cardiovascular disease reporter at STAT, covering heart, stroke, and metabolic conditions. You can reach Liz on Signal at LizC.22. NEW ORLEANS — A pill designed to further lower ...
Seeking Alpha

Merck stock dips after narrowing full-year sales outlook

Merck (MRK) shares fell 2% in premarket trading on Thursday even after topping Wall Street expectations with its Q3 results, while narrowing the top end of its full-year 2025 sales outlook. The Rahway ...
Fox Business

Merck breaks ground on $3B manufacturing plant in Virginia

Merck on Monday announced the groundbreaking of its new Virginia pharmaceutical manufacturing facility, a cornerstone of the company’s $70 billion U.S. investment strategy. The 400,000-square-foot ...
STAT

Merck rolls out some showstoppers at a major cancer conference. Its future may depend on them

Andrew Joseph covers health, medicine, and the biopharma industry in Europe. You can reach Andrew on Signal at drewqjoseph.45. BERLIN — At a prime-time session on Saturday at a major cancer conference ...
Seeking Alpha

Merck: A Race Against The Keytruda Clock

Merck is attractively valued, boasting strong free cash flow, robust margins, and a leading position in oncology with Keytruda. MRK faces a looming patent cliff for Keytruda in 2028, but a strong late ...
Nasdaq

Evaxion Out-licenses Vaccine Candidate EVX-B3 To Merck & Co.

(RTTNews) - TechBio company Evaxion A/S (EVAX) announced Thursday it has out-licensed its vaccine candidate EVX-B3 to Merck & Co., Inc. or MSD (MRK), as per the option and license agreement entered ...
Wall Street Journal

Merck to Lay Off Workers and Narrows Guidance as Earnings Fall

Merck MRK1.52%increase; green up pointing triangle & Co. said it is embarking on a multi-year cost-savings plan, which includes cuts to its workforce and real-estate footprint, as it looks to redirect ...
The Motley Fool

Merck Just Announced a $10 Billion Deal That Will Help Diversify Its Business

Merck aims to boost its business by buying Verona Pharma for $10 billion. Through the deal, it will add Ohtuvayre -- a treatment for COPD -- to its portfolio. With the stock valued at only 12 times ...
Bloomberg L.P.

Merck Nears $10 Billion Deal for Drugmaker Verona, FT Says

Merck & Co. is closing in on an approximately $10 billion deal to acquire respiratory drugmaker Verona Pharma, the Financial Times reported Merck would pay $107 per American depository share for the ...